Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 182 participants.

Also called NCT04784013

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 182 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04784013
Other papers using this trial's data
  • Very High-Power Ablation for Contiguous Pulmonary Vein Isolation: Results From the Randomized POWER PLUS Trial JACC. Clinical electrophysiology, 2023-04 DOI, PubMed 36752467

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Austria, Belgium, Netherlands, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04784013. Randomized; no masking; primary purpose treatment. Start 2021-03-24 (actual); primary completion 2021-10-22 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Very High Power Ablation in Patients With Atrial Fibrillation Scheduled for a First Pulmonary Vein Isolation
Acronym
POWER-PLUS
Intervention (Procedure)
Conventional CLOSE-guided pulmonary vein isolation
Intervention (Procedure)
High power short duration pulmonary vein isolation
Lead sponsor
AZ Sint-Jan AV (class: other)

Record details

Record id
cardio:ct-nct04784013
Content hash
e14f6b5b11265ded391eb90f857516c41cbf97e73b416648bdb6dafaea963570